SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001144204-14-017727
Filing Date
2014-03-26
Accepted
2014-03-25 21:10:25
Documents
1
Group Members
ALAIN L. AZANDR. JAMES I. HEALYDR. MICHAEL F. POWELLERIC P. BUATOISSOFINNOVA MANAGEMENT VI, L.L.C.SOFINNOVA VENTURE AFFILIATES VI, L.P.SOFINNOVA VENTURE PARTNERS VI GMBH & CO. KG

Document Format Files

Seq Description Document Type Size
1 SC 13D/A v372599_sc13da.htm SC 13D/A 148050
  Complete submission text file 0001144204-14-017727.txt   149973
Mailing Address 2800 SAND HILL ROAD SUITE 150 MENLO PARK CA 94025
Business Address 2800 SAND HILL ROAD SUITE 150 MENLO PARK CA 94025 650-681-8420
SOFINNOVA VENTURE PARTNERS VI L P (Filed by) CIK: 0001211465 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 525 UNIVERSITY AVENUE SUITE 610 PALO ALTO CA 94301
Business Address 525 UNIVERSITY AVENUE SUITE 610 PALO ALTO CA 94301 6504625800
Ocera Therapeutics, Inc. (Subject) CIK: 0001274644 (see all company filings)

IRS No.: 631192270 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-86177 | Film No.: 14717218
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences